Amylyx Pharmaceuticals, Inc. (AMLX): Total Liabilities
$27.39M
As of 2025-12-31
$25.40M
As of 2026-06-30
-18.6%
3-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $27.39M | -5.1% | 2026-03-03, Balance as of period end |
| 2024-12-31 | $28.87M | -65.6% | 2026-03-03, Balance as of period end |
| 2023-12-31 | $84.02M | +65.2% | 2025-03-04, Balance as of period end |
| 2022-12-31 | $50.85M | +191.7% | 2024-02-22, Balance as of period end |
| 2021-12-31 | $17.43M | n/a | 2023-03-13, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Amylyx Pharmaceuticals, Inc. (AMLX) | 2025-12-31 | $27.39M | -5.1% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $71.53B | -6.1% |
| TherapeuticsMD, Inc. (TXMD) | 2025-12-31 | $10.78M | -5.9% |
| Pfizer Inc (PFE) | 2025-12-31 | $121.39B | -2.8% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $117.67B | +8.3% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $99.59M | +24.7% |
| Provectus Biopharmaceuticals, Inc. (PVCT) | 2025-12-31 | $7.00M | +0.4% |
| Lisata Therapeutics, Inc. (LSTA) | 2025-12-31 | $3.14M | -44.7% |
| Heron Therapeutics, Inc. (HRTX) | 2025-12-31 | $241.54M | -9.5% |
Compare AMLX, BMY, TXMD, PFE side by side · Screen every company in Pharmaceutical Preparations ↗